No Need for Open-Chest Surgery: Stem Cell Patch Enables Minimally Invasive Heart Repair
Release time:
2025-12-12
Recently, a joint research team from the Mayo Clinic and the University of Nebraska Medical Center published a breakthrough study in the Journal of Biomedical Materials Research—they successfully developed a minimally implantable stem cell patch that can repair damaged hearts without open-chest surgery, providing a safer treatment option for heart failure patients. This achievement signifies the deep integration of regenerative medicine and minimally invasive interventional technology, which is expected to reshape the clinical approach to heart repair.
Heart failure is one of the leading causes of death worldwide. Among traditional treatment methods, in addition to medication control, severely ill patients often rely on mechanical pump assistance or even heart transplantation. However, the former carries a high risk of complications, while the latter faces a scarcity of donors. Previously, scientists attempted to replace damaged tissue with stem cell-derived cardiomyocytes, but the need for open-chest surgery deterred most patients. Even when using induced pluripotent stem cells (iPSCs) reprogrammed from skin or blood cells and cultured into cardiomyocytes, the safe and efficient delivery of these cells remained a critical bottleneck.
To address this challenge, the research team adopted an interdisciplinary engineering and biological perspective to design a flexible, ultra-thin stem cell patch. Its core consists of a nano-microfiber hybrid scaffold coated with gelatin as a substrate, which can carry reprogrammed and cultured human cardiomyocytes, vascular cells, and fibroblasts, forming a living, autonomously beating heart-like tissue. Before transplantation, the patch is infused with bioactive components such as fibroblast growth factor to promote angiogenesis and enhance cell survival.
More ingeniously, the patch can be folded like paper and precisely delivered to the target area of the heart through a small chest incision via a thin catheter. Once in place, it automatically unfolds and tightly adheres to the heart wall. Fixed with a biocompatible surgical adhesive, it avoids damage to surrounding tissues while ensuring stable anchoring. Preclinical trials showed that, compared to traditional methods, this minimally invasive implantation significantly improved heart function, reduced scar formation, promoted blood vessel growth, and simultaneously alleviated inflammation while activating the heart’s self-repair capabilities.
The breakthrough of this technology lies not only in avoiding high-risk open-chest surgery but also in the clever integration of regenerative medicine with minimally invasive interventions, overcoming the delivery barrier of stem cell therapy. The team emphasized that patients with severe heart failure currently have limited treatment options, and the patch solution offers a safer alternative for this population.
If this technology can be applied on a large scale in the future, it may significantly reduce hospitalization rates and medical burdens for heart failure patients, impacting the global landscape of cardiovascular health. In the long term, it could provide a replicable template for regenerative therapies for other organs, accelerating the translation of regenerative medicine into clinical practice. From "open-chest heart replacement" to "patch-based heart repair," this quiet medical revolution is sustaining life in a gentler way.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
